| pubmed-article:9723952 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0005854 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0242643 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0234621 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0182537 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C0205197 | lld:lifeskim |
| pubmed-article:9723952 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:9723952 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9723952 | pubmed:dateCreated | 1998-11-13 | lld:pubmed |
| pubmed-article:9723952 | pubmed:abstractText | 1. Homozygously mdr1a gene disrupted mice (mdr1a(-/-) mice) and wild type mice (mdr1a(+/+) mice) were used to develop a method for P-glycoprotein (P-gp) function imaging non-invasively and to study the effect of a P-gp reversal agent on its function in vivo. 2. [11C]verapamil (0.1 mg/kg) was administered and the changes in tissue concentrations were determined ex vivo by organ extirpation and in vivo with PET. To block P-gp function, cyclosporin A was administered. 3. Biodistribution studies revealed 9.5-fold (P < 0.001) and 3.4-fold (P < 0.001) higher [11C]verapamil in the brain and testes of mdr1a(-/-) mice than in mdr1a(+/+) mice. Cyclosporin A (25 mg/kg) increased [11C]verapamil levels in the brain and testes of mdr1a(+/+) mice in both cases 3.3-fold (P < 0.01 (brain); P < 0.001 (testes)). Fifty mg/kg cyclosporin A increased [11C]verapamil in the brain 10.6-fold (P < 0.01) and in the testes 4.1-fold (P < 0.001). No increases were found in the mdr1a(-/-) mice. This indicates complete inhibition of P-gp mediated [11C]verapamil efflux. 4. Positron camera data showed lower [11C]verapamil levels in the brain of mdr1a(+/+) mice compared to those in mdr1a(-/-) mice. [11C]verapamil accumulation in the brain of mdr1a(+/+) mice was increased by cyclosporin A to levels comparable with those in mdr1a(-/-) mice, indicating that reversal of P-gp mediated efflux can be monitored by PET. 5. We conclude that cyclosporin A can fully block the P-gp function in the blood brain barrier and the testes and that PET enables the in vivo measurement of P-gp function and reversal of its function non-invasively. | lld:pubmed |
| pubmed-article:9723952 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9723952 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9723952 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9723952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9723952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9723952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9723952 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9723952 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9723952 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:VaalburgWW | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:de VriesE GEG | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:FranssenE JEJ | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:SchinkelA HAH | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:WillemsenA... | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:Van der... | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:HendrikseN... | lld:pubmed |
| pubmed-article:9723952 | pubmed:author | pubmed-author:FluksEE | lld:pubmed |
| pubmed-article:9723952 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9723952 | pubmed:volume | 124 | lld:pubmed |
| pubmed-article:9723952 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9723952 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9723952 | pubmed:pagination | 1413-8 | lld:pubmed |
| pubmed-article:9723952 | pubmed:dateRevised | 2008-11-20 | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:meshHeading | pubmed-meshheading:9723952-... | lld:pubmed |
| pubmed-article:9723952 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9723952 | pubmed:articleTitle | Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. | lld:pubmed |
| pubmed-article:9723952 | pubmed:affiliation | PET-Center, Department of Medical Oncology, Groningen University Hospital, The Netherlands. | lld:pubmed |
| pubmed-article:9723952 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9723952 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9723952 | lld:pubmed |
